BCLI Brainstorm Cell Therapeutics Inc.

+0.14  (+4%)
Previous Close 3.38
Open 3.42
Price To Book 7.33
Market Cap 72889474
Shares 20,707,237
Volume 45,790
Short Ratio
Av. Daily Volume 58,865

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data mid-2020. Interim safety analysis due by July 2019.
Amytrophic lateral sclerosis (ALS)
Phase 2 trial to commence early 2019.
Progressive Multiple Sclerosis